TRDA Form 4: Entrada CFO trades 8,910 shares at ~$9.98 avg

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (TRDA) reported an insider stock sale by its Chief Financial Officer. On 11/21/2025, the CFO sold 8,910 shares of common stock in an open-market transaction at a weighted average price of $9.9811 per share. The shares were sold in multiple trades at prices ranging from $9.95 to $10.05.

The transaction was executed pursuant to a Rule 10b5-1 trading plan that the reporting person adopted on March 6, 2025. Following this sale, the CFO beneficially owns 110,026 shares of Entrada Therapeutics common stock in direct ownership.

Insider Trade Summary

Net Seller: 8,910 shares ($88,932)

Net Sell 1 txn

Insider WENTWORTH KORY JAMES

Role Chief Financial Officer

Sold 8,910 shs ($89K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,910	$9.9811	$89K

Holdings After Transaction: Common Stock — 110,026 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WENTWORTH KORY JAMES

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/21/2025		S(1)		8,910	D	$9.9811(2)	110,026	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Entrada Therapeutics (TRDA) report in this Form 4?

The Chief Financial Officer of Entrada Therapeutics (TRDA) reported selling 8,910 shares of common stock on 11/21/2025 in an open-market transaction.

At what price were the TRDA shares sold by the CFO?

The CFO sold the 8,910 TRDA shares at a weighted average price of $9.9811 per share, with individual trades executed between $9.95 and $10.05.

How many Entrada Therapeutics shares does the CFO own after this sale?

After the reported sale, the Chief Financial Officer beneficially owns 110,026 shares of Entrada Therapeutics common stock in direct ownership.

Was the TRDA insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected under a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.

Who is the reporting person in this Entrada Therapeutics (TRDA) Form 4?

The reporting person is the Chief Financial Officer of Entrada Therapeutics, Inc., who filed the Form 4 as an officer of the issuer.

How are the TRDA sale prices described in the Form 4 footnotes?

The Form 4 notes that the reported price is a weighted average and that the shares were sold in multiple transactions between $9.95 and $10.05, with full trade details available upon request.